Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127009701 | 12700970 | 1 | I | 20160815 | 20160831 | 20160831 | EXP | GB-MLMSERVICE-20160809-0384785-1 | GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2016-00137 | ALKEM | 44.00 | YR | M | Y | 0.00000 | 20160830 | CN | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127009701 | 12700970 | 1 | PS | QUETIAPINE FUMARATE. | QUETIAPINE FUMARATE | 1 | 50 MG, BID | Y | 201504 | 50 | MG | Q12H | |||||||
| 127009701 | 12700970 | 2 | I | QUETIAPINE FUMARATE. | QUETIAPINE FUMARATE | 1 | 100 MG, BID | Y | 201504 | 100 | MG | Q12H | |||||||
| 127009701 | 12700970 | 3 | I | QUETIAPINE FUMARATE. | QUETIAPINE FUMARATE | 1 | 125 MG, BID | Y | 201504 | 125 | MG | Q12H | |||||||
| 127009701 | 12700970 | 4 | I | QUETIAPINE FUMARATE. | QUETIAPINE FUMARATE | 1 | 150 MG, OD | Y | 201504 | 150 | MG | Q12H | |||||||
| 127009701 | 12700970 | 5 | I | QUETIAPINE FUMARATE. | QUETIAPINE FUMARATE | 1 | 150 MG, BID | Y | 201504 | 150 | MG | Q12H | |||||||
| 127009701 | 12700970 | 6 | I | VENLAFAXINE | VENLAFAXINE HYDROCHLORIDE | 1 | UNKNOWN | Y | 0 | ||||||||||
| 127009701 | 12700970 | 7 | I | VENLAFAXINE | VENLAFAXINE HYDROCHLORIDE | 1 | 300 MG, OD | Y | 0 | 300 | MG | Q12H | |||||||
| 127009701 | 12700970 | 8 | C | CLOMETHIOZOLE | 2 | 384 MG, OD | 0 | 384 | MG | Q12H | |||||||||
| 127009701 | 12700970 | 9 | C | ZOMORPH | MORPHINE SULFATE | 1 | 20 MG, OD | 0 | 20 | MG | Q12H | ||||||||
| 127009701 | 12700970 | 10 | C | PREGABALIN. | PREGABALIN | 1 | 300 MG, OD | 0 | 300 | MG | Q12H | ||||||||
| 127009701 | 12700970 | 11 | C | PROCYCLIDINE | PROCYCLIDINE | 1 | 2.5 MG, TID | 0 | 2.5 | MG | Q8H | ||||||||
| 127009701 | 12700970 | 12 | C | DIAZEPAM. | DIAZEPAM | 1 | 2 MG, TID | 0 | 2 | MG | Q8H |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127009701 | 12700970 | 1 | Product used for unknown indication |
| 127009701 | 12700970 | 6 | Product used for unknown indication |
| 127009701 | 12700970 | 8 | Product used for unknown indication |
| 127009701 | 12700970 | 9 | Product used for unknown indication |
| 127009701 | 12700970 | 10 | Product used for unknown indication |
| 127009701 | 12700970 | 11 | Product used for unknown indication |
| 127009701 | 12700970 | 12 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127009701 | 12700970 | OT |
| 127009701 | 12700970 | LT |
| 127009701 | 12700970 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127009701 | 12700970 | Drug interaction | |
| 127009701 | 12700970 | Encephalitis | |
| 127009701 | 12700970 | Hypertension | |
| 127009701 | 12700970 | Lactic acidosis | |
| 127009701 | 12700970 | Serotonin syndrome | |
| 127009701 | 12700970 | Tardive dyskinesia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |